
Ayahuasca and DMT research
- 01
A: It is promising, but still early. Most ayahuasca studies on addiction are observational, and the first randomised trials are still missing.
In Canada (2013), 12 people in a First Nations community joined retreats with four days of group counselling and two ayahuasca ceremonies. Six months later, problematic cocaine use had dropped significantly, and alcohol and tobacco use went down. Cannabis and opiate use did not. It was a small study with no control group.
In February 2026, Brazilian researchers reviewed the studies on ayahuasca, DMT and mental health. Long-term ceremony users, large surveys and studies of first-time ceremonies all point to less alcohol, tobacco and drug use. Their conclusion: promising, especially in structured and supportive settings, but randomised trials are needed to confirm it.
Sources: Thomas et al., Current Drug Abuse Reviews · Current Addiction Reports, 2026
- 02
A: Yes. This is no longer fringe science. Some of the world's leading universities now have teams dedicated to it.
Johns Hopkins University opened the Center for Psychedelic and Consciousness Research in 2019, the first of its kind in the US, with $17 million in private funding. It studies psilocybin for opioid addiction, alcohol use disorder, smoking, depression and PTSD, and its team has run psilocybin studies for over 20 years. In 2021 it received the first US government (NIH) grant in over 50 years to study a classic psychedelic as treatment.
Massachusetts General Hospital, a Harvard Medical School teaching hospital, opened the Center for the Neuroscience of Psychedelics in 2021. It studies how psychedelics act on the brain and whether they can help with depression and PTSD.
Imperial College London runs trials with DMT, the active compound in ayahuasca. NYU and Stanford have led trials on psilocybin and ibogaine, and the Federal University of Rio Grande do Norte in Brazil ran the first placebo-controlled ayahuasca trial.
Sources: Johns Hopkins Medicine · JHU Hub · The Harvard Crimson
- 03
A: The first placebo-controlled trial says it might. In Brazil, 29 people with treatment-resistant depression got one dose of ayahuasca or a placebo. One week later, 64% of the ayahuasca group responded, against 27% on placebo.
It was one small trial, and larger studies are needed. But it was the first time ayahuasca was tested the way medicines are tested.
Source: Palhano-Fontes et al., Psychological Medicine (2019)
- 04
A: DMT is the main active compound in ayahuasca. Ayahuasca is a brew of two plants: one contains DMT, the other makes it work when you drink it.
In 2026, Imperial College London tested DMT on 34 adults with moderate to severe depression who had already tried at least two treatments. With therapy support, one dose of DMT worked clearly better than placebo after one and two weeks, and the effect lasted up to three months, for some up to six. There were no serious side effects. The trial was small and funded by the company that makes the drug.
Also in 2026, an inhaled form of 5-MeO-DMT, a related compound, was tested against placebo at 16 European clinics for treatment-resistant depression. After one week, 57.5% of patients were in remission, against 0% on placebo. It is still experimental.
Sources: Imperial College London (Nature Medicine) · JAMA Psychiatry, 2026 (UTHealth summary)
- 05
A: Psilocybin is the active compound in magic mushrooms, and it is the most studied plant medicine for addiction so far.
Smoking (Johns Hopkins, 2026): 82 smokers were randomised, and all got 13 weeks of therapy. After six months, 17 in the psilocybin group had verifiably quit, against 4 with the nicotine patch.
Alcohol (NYU, 2022): 93 adults with alcohol use disorder took part in a double-blind trial. In the 32 weeks after treatment, the psilocybin group had heavy drinking days on about 10% of days, against 24% on placebo.
Sources: NPR on the Johns Hopkins study · Bogenschutz et al., JAMA Psychiatry
- 06
A: Ibogaine comes from the root of an African shrub. In a Stanford study (2024), 30 special forces veterans with brain injuries were treated with ibogaine plus magnesium in Mexico. One month later, PTSD symptoms were down 88% and depression 87% on average. There were no heart problems, but there was no control group either.
In 2025, Texas set aside $50 million for clinical trials aimed at FDA approval of ibogaine for addiction. Ibogaine can cause serious heart problems, so it should only ever be used with medical supervision.
Sources: Stanford Medicine · Drugs.com
- 07
A: No. The research is promising, but it is early. Most studies are small, some have no control group, and several are funded by companies. There are no large randomised trials of ayahuasca for addiction yet.
What the studies do agree on is that the setting matters. The best results come with preparation, support and integration afterwards, not with the substance alone.
For Jakob it wasn't a cure. It was the first place he stopped running.
- 08
A: No. Ayahuasca can be dangerous together with antidepressants (SSRIs) and some other medicines, with heart conditions, and for people with a history of psychosis.
Never stop or change medication without talking to your doctor, and choose a retreat that screens you medically before you go.
- 09
A: After 20 years of addiction, nothing Jakob tried held, until ten days and four ayahuasca ceremonies in Costa Rica. His story is one experience, not proof. That's why he wants you to see what scientists have actually found, including the limits. This page is updated when important new studies come out.
Considering plant medicine? Book a free 30-min call →
This page shares research and Jakob's personal experience. It is not medical, legal or professional advice. Ayahuasca and DMT are illegal in many countries, including Denmark.
